Depressed bronchoalveolar urokinase activity in patients with adult respiratory distress syndrome

New England Journal of Medicine

Volumn 322, Issue 13, 1990, Pages 890-897

  Bertozzi, Paul ^a   Astedt, Birgir ^c   Zenzius, Laura ^a,b   Lynch, Karen ^b   Lemaire, Françoise ^d   Chapman, Harold A ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c LUND UNIVERSITY   (Sweden)

^d HENRI MONDOR HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRIN; FIBRONECTIN; PLASMINOGEN ACTIVATOR;

ADULT RESPIRATORY DISTRESS SYNDROME; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; LUNG; PRIORITY JOURNAL;

ADULT; ANTIGENS; ANTIPLASMIN; BRONCHOALVEOLAR LAVAGE FLUID; FEMALE; FIBRIN; FIBRONECTINS; HUMAN; LUNG DISEASES; MALE; MIDDLE AGE; RESPIRATORY DISTRESS SYNDROME, ADULT; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.; URINARY PLASMINOGEN ACTIVATOR;

EID: 0025318632     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJM199003293221304     Document Type: Article

References (35)

1. Spencer H. Pathology of the lung, excluding pulmonary tuberculosis. 3rd ed. New York: Pergamon Press, 1977:235–40.
2. Bachofen A, Weibel ER. Alterations of the gas exchange apparatus in adult respiratory insufficiency associated with septicemia. Am Rev Respir Dis 1977; 116: 589–615.
3. Pratt P. Pathology of adult respiratory distress syndrome. In: Thurlbeck WM, Abell MR, eds. The lung: structure, function, and disease. Baltimore: Williams & Wilkins, 1978:45–7.
4. Basset F, Ferrans VJ, Soler P, Takemura T, Fukuda Y, Crystal RG. Intraluminal fibrosis in interstitial lung disorders. Am J Pathol 1986; 122: 443–61.
5. Fukuda Y, Ishizaki M, Masuda Y, Kimura G, Kawanami O, Masugi Y. The role of intraalveolar fibrosis in the process of pulmonary structural remodeling in patients with diffuse alveolar damage. Am J Pathol 1987; 126: 171–82.
6. Bitterman PD, Rennard SI, Adelberg S, Crystal RG. Role of fibronectin as a growth factor for fibroblasts. J Cell Biol 1983; 97: 1925–32.
7. Grinnell F, Feld M, Minter D. Fibroblast adhesion to fibrinogen and fibrin substrata: requirement for cold-insoluble globulin (plasma fibronectin). Cell 1980; 19: 517–25.
8. Zapol WM, Trelstad RL, Coffey JW, Tsai I, Salvador RA. Pulmonary fibrosis in severe acute respiratory failure. Am Rev Respir Dis 1979; 119: 547–54.
9. Chapman HA, Allen CL, Stone OL. Abnormalities in pathways of alveolar fibrin turnover among patients with interstitial lung disease. Am Rev Respir Dis 1986; 133: 437–43.
10. Reilly JJ, Chapman HA Jr. Association between alveolar macrophage plasminogen activator activity and indices of lung function in young cigarette smokers. Am Rev Respir Dis 1988; 138: 1422–8.
11. Lowry OH, Rosenbrough NJ, Farr AL, Randall RJ. Protein measurement with the folin phenol reagent. J Biol Chem 1951; 193: 265–75.
12. Loskutoff DJ, Edgington TS. An inhibitor of plasminogen activator in rabbit endothelial cells. J Biol Chem 1981; 256: 4142–5.
13. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680–5.
14. Astedt B, Holmberg L, Lecander I, Thorell J. Radioimmunoassay of urokinase for quantification of plasminogen activators released in ovarian tumour cultures. Eur J Cancer 1981; 17: 239–44.
15. Jonsson Berg A-K, Lecander I, Astedt B. An immunosorbent activity assay for urokinase. Fibrinolysis 1988; 2: 145.
16. Granelli-Piperno A, Reich E. A study of proteases and protease-inhibitor complexes in biological fluids. J Exp Med 1978; 148: 223–34.
17. Vassalli JD, Dayer JM, Wohlwend A, Belin D. Concomitant secretion of prourokinase and of a plasminogen activator-specific inhibitor by cultured human monocytes-macrophages. J Exp Med 1984; 159: 1653–68.
18. Erickson LA, Ginsberg MH, Loskutoff DJ. Detection and partial characterization of an inhibitor of plasminogen activator in human platelets. J Clin Invest 1984; 74: 1465–72.
19. Dosne AM, Dupuy E, Bodevin E. Production of a fibrinolytic inhibitor by cultured endothelial cells derived from human umbilical vein. Thromb Res 1978; 12: 377–87.
20. Lecander I, Astedt B. Isolation of a new specific plasminogen activator inhibitor from pregnancy plasma. Br J Haematol 1986; 62: 221–8.
21. Chapman HA, Stone OL. A fibrinolytic inhibitor of human alveolar macrophages: induction with endotoxin. Am Rev Respir Dis 1985; 132: 569–75.
22. Colton T. Statistics in medicine. 1st ed. Boston: Little, Brown, 1974:219–28.
23. Bowen RM, Hoidal JR, Estensen RD. Urokinase-type plasminogen activator in alveolar macrophages and bronchoalveolar lavage fluid from normal and smoke-exposed hamsters and humans. J Lab Clin Med 1985; 106: 667–73.
24. Chmielewska J, Rånby M, Wiman B. Evidence for a rapid inhibitor to tissue plasminogen activator in plasma. Thromb Res 1983; 31: 427–36.
25. Sanzo MA, Marasa JC, Wittwer AJ, Siegel NR, Harakas NK, Feder J. Purification and characterization of a tissue plasminogen activator-inhibitor complex from human umbilical vein endothelial cell conditioned medium. Biochemistry 1987; 26: 7443–9.
26. Reynolds J, Davis JT. Injuries of the chest wall, pleura, pericardium, lungs, bronchi and esophagus. Radiol Clin North Am 1966; 4: 383–401.
27. Wiot JF. The radiologic manifestations of blunt chest trauma. JAMA 1975; 231: 500–3.
28. Kruithof EK, Gudinchet A, Bachmann F. Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states. Thromb Haemost 1988; 59: 7–12.
29. Baker JB, Low DA, Simmer RL, Cunningham DD. Protease-nexin: a cellular component that links thrombin and plasminogen activator and mediates their binding to cells. Cell 1980; 21: 37–45.
30. Taylor FB Jr, Abrams ME. Effect of surface active lipoprotein on clotting and fibrinolysis, and of fibrinogen on surface tension of surface active lipoprotein: with a hypothesis on the pathogenesis of pulmonary atelectasis and hyaline membrane in respiratory distress syndrome of the newborn. Am J Med 1966; 40: 346–50.
31. Seeger W, Stohr G, Wolf HR, Neuhof H. Alteration of surfactant function due to protein leakage: special interaction with fibrin monomer. J Appl Physiol 1985; 58: 326–38.
32. Hallman M, Spragg R, Harrell JH, Moser KM, Gluck L. Evidence of lung surfactant abnormality in respiratory failure: study of bronchoalveolar lavage phospholipids, surface activity, phospholipase activity, and plasma myoinositol. J Clin Invest 1982; 70: 673–83.
33. Mason RJ. Pulmonary alveolar type II epithelial cells and adult respiratory distress syndrome. West J Med 1985; 143: 611–5.
34. Dvorak HF. Tumors: wounds that do not heal: similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315: 1650–9.
35. Idell S, James KK, Levin EG, et al. Local abnormalities in coagulation and fibrinolytic pathways predispose to alveolar fibrin deposition in the adult respiratory distress syndrome. J Clin Invest 1989; 84: 695–705.